Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 60,201 Shares of Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 60,201 shares of Eliem Therapeutics stock in a transaction on Friday, July 19th. The shares were sold at an average price of $7.21, for a total value of $434,049.21. Following the sale, the executive vice president now directly owns 100,322 shares of the company’s stock, valued at $723,321.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Valerie Morisset also recently made the following trade(s):

• On Monday, July 22nd, Valerie Morisset sold 69,005 shares of Eliem Therapeutics stock. The stock was sold at an average price of $8.03, for a total value of $554,110.15.
• On Wednesday, July 17th, Valerie Morisset sold 3,207 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.91, for a total value of $22,160.37.
• On Monday, July 15th, Valerie Morisset sold 42,377 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $297,062.77.
• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.11, for a total transaction of $355,500.00.
• On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.66, for a total transaction of $39,500.46.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.76, for a total value of $338,000.00.

Eliem Therapeutics Price Performance

NASDAQ ELYM traded up $0.61 during midday trading on Tuesday, hitting $8.93. 292,593 shares of the company traded hands, compared to its average volume of 458,660. The company has a market cap of $265.67 million, a PE ratio of -16.85 and a beta of -0.33. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55. The company’s 50-day simple moving average is $7.66 and its 200-day simple moving average is $5.03.

Eliem Therapeutics (NASDAQ:ELYM) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter.

Institutional Trading of Eliem Therapeutics

An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC bought a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned about 0.05% of Eliem Therapeutics as of its most recent SEC filing. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.